An Intrinsic Calculation For Raffles Medical Group Ltd (SGX:BSL) Suggests It's 50% Undervalued
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 07 2024
0mins
Should l Buy ?
Source: Yahoo Finance
Valuation Insights: Raffles Medical Group's estimated fair value is S$1.78, indicating a potential 50% undervaluation compared to its current share price of S$0.90, and significantly higher than the analyst price target of S$1.10.
SWOT Analysis Overview: The company shows strengths in low debt and covered dividends, but faces weaknesses with declining earnings and slower revenue growth forecasts, while opportunities include faster annual earnings growth than the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
